GlassScriptPhysician profile
Shannon Mayer
NPI 1306509138
$2,219.30
in general payments reported to CMS, 2019-2025
26 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $169 · 2023: $329 · 2024: $697 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $390.50 | 2023-2025 | Extended Holter, (5044) Mcot, Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $353.89 | 2022-2025 | Lifevest |
| Abbott Laboratories | $301.98 | 2021-2025 | Esprit |
| Novo Nordisk INC | $215.51 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $167.92 | 2023-2025 | Opticross, Watchman Access System |
| Edwards Lifesciences Corporation | $117.78 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $93.50 | 2025 | |
| Cardiva Medical, INC. | $92.76 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire |
| Novartis Pharmaceuticals Corporation | $48.43 | 2025 | |
| Amgen INC. | $47.85 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $45.06 | 2024-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $41.92 | 2022-2023 | Cobalt Dr Mri Surescan |
| Pfizer INC. | $40.65 | 2023-2024 | |
| Atricure, INC. | $37.73 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Merck Sharp & Dohme LLC | $27.27 | 2023-2024 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.00 | 2024 | Xarelto |
| Altathera Pharmaceuticals LLC | $26.46 | 2023-2024 | Sotalol Hydrochloride |
| Kestra Medical Technology Services, INC. | $26.35 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $22.74 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $15.57 | 2022 | |
| Impulse Dynamics (USA) INC. | $14.74 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $14.21 | 2024 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $14.20 | 2024 | Edarbyclor |
| Kiniksa Pharmaceuticals, LTD. | $13.65 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2025 | Jardiance |
| Vivaquant INC, Dba Rhythm Express | $8.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.